Defence Therapeutics Inc C.DTC

Alternate Symbol(s): DTCFF

Healthcare Biotechnology

Defence Therapeutics Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and engineering the radio-immuno-conjugate and antibody drug conjugates (ADC) products using its proprietary platform in addition to immune-oncology vaccines. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer and mRNA vaccination.